NCT02751307View on ClinicalTrials.gov

Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Metabolic Syndrome
Interventions
DRUG

metformin 500 mg

metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d

DRUG

clozapine 100 mg

Clozapine dose remained unchanged during metformin intervention period in recruited patients.

All Listed Sponsors
collaborator

Taipei City Hospital

OTHER_GOV

lead

Taipei Medical University WanFang Hospital

OTHER

NCT02751307 - Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities | Biotech Hunter | Biotech Hunter